부산대학교 도서관

BRCA1/2 carriers have a higher risk of developing breast and ovarian cancer at a younger age.?Preimplantation genetic diagnosis (PGD) and prenatal diagnosis (PND) are two of the few options available to avoid transmitting the mutation.?To inform the bioethics debate about authorization, a contingent valuation survey elicited preferences regarding access to PGD and PND from a sample of 460 unaffected by cancer BRCA1/2 carriers (GENEPSO cohort).?We find that the respondents can be classified into three groups: one opposed to PGD/PND (28.3%), one strongly in favour of PGD/PND (45.8%), and one in an intermediate position (25.9%).?We look for the determinants of these preferences, especially of the willingness to pay for PGD/PND.?Overall, we find that BRCA1/2 carriers support access to PGD/PND, which has implications for recommendations to decision-makers. JEL Codes: C01, C83, D04, D79, I19.